Table 8.

Potential advantages of allogeneic immunotherapy for solid tumor

  • Donor immune system healthy/chemotherapy naïve

  • Donor T cells can target minor histocompatibility antigen (mHa) expressed on the tumor

  • Donor T cells not tolerized to tumor antigens

  • Donor lymphocyte infusions (DLI) can be given should T cells become tolerized to the tumor

 

  • Donor immune system healthy/chemotherapy naïve

  • Donor T cells can target minor histocompatibility antigen (mHa) expressed on the tumor

  • Donor T cells not tolerized to tumor antigens

  • Donor lymphocyte infusions (DLI) can be given should T cells become tolerized to the tumor

 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal